362 related articles for article (PubMed ID: 31696357)
1. Treatment of hyperphosphatemia: the dangers of high PTH levels.
Bacchetta J
Pediatr Nephrol; 2020 Mar; 35(3):493-500. PubMed ID: 31696357
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
4. Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies.
Haffner D; Schaefer F
Pediatr Nephrol; 2013 Apr; 28(4):537-45. PubMed ID: 22893310
[TBL] [Abstract][Full Text] [Related]
5. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
11. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio.
Fehmi H; Osman Y; Bhat S; Nguyen K; Daramola O; Cantor T; Monier-Faugere MC; Yee J; Malluche HH
Clin Nephrol; 2009 Mar; 71(3):267-75. PubMed ID: 19281737
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
15. [How to manage mineral metabolism disorders in renal failure].
Jean G
Presse Med; 2011 Nov; 40(11):1043-52. PubMed ID: 21885239
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.
Bacchetta J; Bernardor J; Garnier C; Naud C; Ranchin B
Calcif Tissue Int; 2021 Jan; 108(1):116-127. PubMed ID: 31996964
[TBL] [Abstract][Full Text] [Related]
17. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
18. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
